{"id":788070,"date":"2023-10-04T10:45:18","date_gmt":"2023-10-04T14:45:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/"},"modified":"2023-10-04T10:45:18","modified_gmt":"2023-10-04T14:45:18","slug":"mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/","title":{"rendered":"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania"},"content":{"rendered":"<h2>\nStrategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BERKELEY, Calif. and MAINZ, Germany, Oct.  04, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yg_2Iwx8rIEQHKJ9HVROLnxVtFegqeFfZX4In8D9jMm2xwzaw_hi5Sz82IQZhY_OIBV-I3Hr-JQlVE7N2xoodh4nh2UnYjZBGPU1mLeq-hs=\" rel=\"nofollow noopener\" target=\"_blank\">Mainz Biomed NV<\/a> (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the live launch of Mainz Biomed\u2019s flagship product, ColoAlert<sup>\u00ae<\/sup> \u2014 a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) &#8211; with strategic partner Bioclinica, a national leader in the Romanian healthcare sector. This partnership signifies a pivotal step towards enhancing healthcare outcomes in the country through advanced diagnostics.<\/p>\n<p>CRC incidence rates in Romania are among the highest in Europe. With no national screening program in place, population data from Romania underscores the urgency to have diagnostic tests publicly available in the country to enhance CRC screening practices. With 1.6 million individuals aged 40 to 49 years, 6.1 million aged 50 to 74 years, and 1.5 million aged over 75 years, the potential market for ColoAlert<sup>\u00ae<\/sup> is substantial, reaching 9.2 million tests per year.<\/p>\n<p>The collaboration with Bioclinica adds significant value to Mainz Biomed&#8217;s mission. Leveraging the renowned expertise and extensive network of Bioclinica, ColoAlert<sup>\u00ae<\/sup> will immediately become available to a large portion of the Romanian population. Bioclinica, a trusted supplier of healthcare products with over 25 years of experience in medical diagnostics, operates 15 associated laboratories and 146 collection points across Romania. Mainz Biomed and Bioclinica will collaborate on co-marketing activities to ensure the successful commercial launch of ColoAlert<sup>\u00ae<\/sup> across the country.<\/p>\n<p>&#8220;We are delighted to see ColoAlert<sup>\u00ae<\/sup> now made available to Romanian\u2019s through our key partnership with Bioclinica,&#8221; commented Darin Leigh, Chief Commercial Officer of Mainz Biomed. &#8220;Our collaboration demonstrates a shared commitment to introducing state-of-the-art diagnostic solutions that can have a transformative impact on public health. Early detection is paramount in combating diseases like colorectal cancer, and our collaboration with Bioclinica exemplifies our mission to ensure more people globally have access to diagnostic tests that can give them a life-changing headstart on this disease.&#8221;<\/p>\n<p>Colorectal cancer remains a significant public health concern globally, with Europeans disproportionately affected. While Europeans make up only one tenth of the world population, about 25% of all annual cancer cases occur in Europe. As the second most lethal cancer on the continent, CRC demands innovative solutions that can transform its diagnosis and treatment landscape. Mainz Biomed&#8217;s ColoAlert<sup>\u00ae<\/sup> addresses this challenge head-on by providing an efficient and user-friendly screening test that empowers individuals to take proactive measures against CRC.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WhHDRpLcg2Z14o50kAvzr3k5BmFIyAi0wWZltD6GVSON6fk_yH85bEBrL6Zfgv1yb-djFSTwQRAonN5zkG-BA7n5ZIpm029l8TCSRmbDme1jOIoGBLoFuKO_2dOASqmoHwnj0r94ggAYkVDxnmyP0h_jWaeO2Mmk2ro0ywgZWNXMnedUBp4yQUZ-VOPAE95Yb02USPBwibhfhSWgmqJM71iSPBo678m__OilEzfTPYc=\" rel=\"nofollow noopener\" target=\"_blank\">Please visit Mainz Biomed\u2019s official website for investors at mainzbiomed.com\/investors\/ for more information.<\/a>\n      <\/p>\n<p>Please follow us to stay up to date:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JXalnK8dTRaTCgWN767CYvsXdzyEDbQtGOlhQo-ibo8i9ZTO8M4W-DeMnM-EzuLNpCXoG-GBWWCUuPeQiUyrDFJ9I-BVfm6s8LhDHnAIrbm1tk1h6akyolNvovw7FmKA\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s0vq8iX0NLwHOJS_qycJ7iU_oLdk70lAUf56oXr26kNqh9viPu0Cx8a-hCI8En7b_x5jycYCNAirB_VinAkB_fZUhsNtpHA1UALIqMs2JGY=\" rel=\"nofollow noopener\" target=\"_blank\"><u>X (Previously Twitter)<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6pE72RobZ8-d8IDy2wtkPsonwwm3rpbZz4Qvruq6VYZ0ry4pSDVzKlW5M7aL1CF76M3MiG4IpsPp6yDDLJ64Zv7azht_ziPWjLKqMtetCZM=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Facebook<\/u><\/a><\/p>\n<p>\n        <strong>About ColoAlert<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <br \/>ColoAlert<sup>\u00ae<\/sup>, Mainz Biomed\u2019s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert<sup>\u00ae<\/sup>\u00a0detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Zk6kdwPZGAQTRkK2jKUHen8I7rMBjE6nSe40r4k7JtnSoxdTzoBty677Khu0QSHWQ-23ikjYNmdNm-KMheb7VHkchUVozUlV0nnYDWdLvPnGgLVSfeK-EGmo2pxI-rv4\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Dollinger et al., 2018<\/strong><\/a>). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert<sup>\u00ae<\/sup>\u00a0will be evaluated in the FDA-registration trial \u2018ReconAAsense.\u2019 Once approved in the US, the Company\u2019s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.<\/p>\n<p>\n        <strong>About Colorectal Cancer<\/strong><br \/>\n        <br \/>Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert<sup>\u00ae<\/sup>\u00a0should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.<\/p>\n<p>\n        <strong>About Mainz Biomed N.V.<\/strong> \u00a0<br \/>Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company\u2019s flagship product is ColoAlert<sup>\u00ae<\/sup>, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert<sup>\u00ae<\/sup> is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed\u2019s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z9HzV9d0Wc5TbJ9lsZgnOAYO4_uvaPhPqJFTV-FBmQQGCNe02swGJKsNvUMkCdxRVn7niAR-gIyCH-LydCW1ubbjzg3lSSMmVk0Z1Kmb2Dg=\" rel=\"nofollow noopener\" target=\"_blank\"><u>mainzbiomed.com<\/u><\/a>.\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>For media inquiries &#8211; <\/strong>\n      <\/p>\n<p>In Europe:<\/p>\n<p>MC Services AG<br \/>Anne Hennecke\/Caroline Bergmann<br \/>+49 211 529252 20<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z9HzV9d0Wc5TbJ9lsZgnOCkbwWCmFazM2mnrEnjm7XUxVxraQPPIgtlorrp9p5kax6KyGGCtnrsrwfs_YBrVaGZ7orYfyS8Vwe-VLVX3fdcNOQvCzVDhT_14fbcWzAd0\" rel=\"nofollow noopener\" target=\"_blank\">mainzbiomed@mc-services.eu<\/a><\/p>\n<p>In the U.S.:<\/p>\n<p>Josh Stanbury<br \/>+1 416 628 7441<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tF-LGXPrCpuxT5HD1e2U8RJEukOxtYCWE-luegpOyHsu4QmgPUlmqQN5jLVSi2LCqC71ApwAG7PxiEnt3kVJwQ==\" rel=\"nofollow noopener\" target=\"_blank\">josh@sjspr.co<\/a><\/p>\n<p>\n        <strong>For investor inquiries, please <\/strong><br \/>\n        <strong>contact<\/strong>\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GXEjPZfHpI2yiHHkjFspzFFVWWMMaeVyVFZfrNe7b4jcVkTU1sOWoSkiJd8EFgyy8d6Jbk5e0PV5aVKfdfXtSei7osIokRtvt1Ph38VaCN4=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>info@mainzbiomed.com<\/strong><\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201coutlook\u201d, and \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company\u2019s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the \u201cSEC\u201d) by the Company. Additional information concerning these and other factors that may impact the Company\u2019s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company\u2019s SEC filings are available publicly on the SEC\u2019s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YTU1ZmU1MWEtYmJjNy00N2EzLThjODYtNTFjZWYxYTM4Y2EyLTEyMzU2NDI=\/tiny\/Mainz-BioMed-NV.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population BERKELEY, Calif. and MAINZ, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the live launch of Mainz Biomed\u2019s flagship product, ColoAlert\u00ae \u2014 a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) &#8211; with strategic partner Bioclinica, a national leader in the Romanian healthcare sector. This partnership signifies a pivotal step towards enhancing healthcare outcomes in the country through advanced diagnostics. CRC incidence rates in Romania are among the highest in Europe. With no national screening program in place, population data from Romania underscores &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-788070","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population BERKELEY, Calif. and MAINZ, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the live launch of Mainz Biomed\u2019s flagship product, ColoAlert\u00ae \u2014 a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) &#8211; with strategic partner Bioclinica, a national leader in the Romanian healthcare sector. This partnership signifies a pivotal step towards enhancing healthcare outcomes in the country through advanced diagnostics. CRC incidence rates in Romania are among the highest in Europe. With no national screening program in place, population data from Romania underscores &hellip; Continue reading &quot;Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-04T14:45:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania\",\"datePublished\":\"2023-10-04T14:45:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/\"},\"wordCount\":1121,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/\",\"name\":\"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==\",\"datePublished\":\"2023-10-04T14:45:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/","og_locale":"en_US","og_type":"article","og_title":"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania - Market Newsdesk","og_description":"Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population BERKELEY, Calif. and MAINZ, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the live launch of Mainz Biomed\u2019s flagship product, ColoAlert\u00ae \u2014 a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) &#8211; with strategic partner Bioclinica, a national leader in the Romanian healthcare sector. This partnership signifies a pivotal step towards enhancing healthcare outcomes in the country through advanced diagnostics. CRC incidence rates in Romania are among the highest in Europe. With no national screening program in place, population data from Romania underscores &hellip; Continue reading \"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-04T14:45:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania","datePublished":"2023-10-04T14:45:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/"},"wordCount":1121,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/","name":"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==","datePublished":"2023-10-04T14:45:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MjQ2NyM0MDE2MTc1MDEjMjIyNDA4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-live-launch-of-coloalert-with-bioclinica-in-romania\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mainz Biomed Announces Live Launch of ColoAlert\u00ae with Bioclinica in Romania"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=788070"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788070\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=788070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=788070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=788070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}